We surveyed 1170 renal cell carcinoma (RCC) patients registered in the data bank of the Nara Uro-oncology Research Group and analyzed retrospectively the clinicopathological features and the outcomes of 35 dialysis patients with RCC who underwent nephrectomy. Twenty-seven patients were men and 8 were women. The mean age was 58.0±9.9(SD) years old. The mean dialysis duration until performing nephrectomy was 101.1±65.5 months. Twenty-seven patients were incidentally diagnosed and 8 patients presented with symptomatic RCC. Acquired renal cystic disease (ARCD) was found in 25 (71.4%) of the 35 patients. The number of RCC patient in each pathological stage was 23 in T1a, 6 in T1b, 4 in T3a, and 2 in T3b. The number of RCC patient with lymph node and distant metastasis was one in N1, 2 in N2 and 3 in M1. The number of RCC patient in each tumor grade was 9 in Grade 1, 21 in Grade 2, and 5 in Grade 3. The histopathological diagnosis was 16 clear cell carcinomas, 9 papillary RCCs, 4 granular cell carcinomas, 4 cyst-associated RCCs, and 2 chromophobe cell carcinomas. Six patients underwent adjuvant interferon therapy. One patient died of lymph node metastasis, one patient died of lung metastasis, and 5 patients died of other causes. The five-year survival rate was 79.4% in all patients 76.7% in ARCD patients, and 91.7% in non-ARCD patients. There was no significant difference in the prognosis between patients with and without ARCD. There was no significant difference in the 5-year overall survival rate in each tumor stage between dialysis and non-dialysis patients with RCC. ARCD did not influence the prognosis of dialysis patients with RCC, but the metastatic RCC resulted in a poor outcome in dialysis patients with RCC.